When will HBMN.SW earnings be announced and why does it matter?

HBMN.SW earnings are scheduled for 23 Jan 2026. The report matters because NAV revisions, realised gains and dividend guidance can cause immediate price moves given the stock’s light intraday volume and fund-style holdings.

What is the current valuation and dividend picture for HBMN.SW stock?

HBMN.SW trades at **PE 17.31** and **price-to-book 0.94** with dividend per share **CHF 7.50**, implying a yield near **3.17%**. These metrics show a modest valuation and income component against book value.

How does Meyka AI rate HBMN.SW stock and what does the forecast show?

Meyka AI rates HBMN.SW **70.04** (Grade B+, Suggestion: BUY). The model projects monthly **CHF 238.04** (+**0.44%**) and flags larger medium-term downside; forecasts are projections, not guarantees.

What are the main risks for HBMN.SW stock after the earnings release?

Key risks include NAV volatility from limited exits, thin trading liquidity (**volume 3367.00**), and concentration in mid-market healthcare investments that can amplify swings in realised gains and share price.

CH Stocks

HBMN.SW HBM Healthcare (SIX) CHF 237.00 pre-earnings 21 Jan 2026: dividend, NAV eye

ByDanny Kontos January 21, 2026January 21, 2026

We see HBMN.SW stock trading at CHF 237.00 intraday on 21 Jan 2026 as investors position for an earnings update due 23 Jan 2026. Traders will watch the announced EPS 13.66 and PE 17.31 alongside the fund’s NAV and upcoming dividend signals. Liquidity is light with volume 3367.00 versus an average of 8582.00, so intraday swings can be amplified. We focus on how valuation, dividend yield and NAV disclosure could move the price into or out of its year high CHF 239.00 band.